Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice

HIGHLIGHTS

• who: Experimental Diab. Res. et al. from the Department of Medicine D, Meir Hospital, Kfar-Sava, Israel and the Sackler Faculty of Medicine, University, Israel have published the article: Omapatrilat, an Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibitor, Attenuates Early Atherosclerosis in Diabetic and in Nondiabetic Low-Density Lipoprotein Receptor-Deficient Mice, in the Journal: (JOURNAL) of 16/07/2002
• what: This study aimed to find whether omapatrilat would attenuate atherogenesis in diabetic (streptozotocin induced) and nondiabetic LDL receptor-deficient mice.
• future: Experiments are needed to clarify this issue.

SUMMARY

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.